Originally isolated from the rabbit brain in 1977, delta sleep-inducing peptide (DSIP) is a naturally occurring nonapeptide created in the hypothalamus. DSIP has been studied in mice, rats, rabbits, cats, and humans for its use in promoting sleep (1).
DSIP is not necessarily a sedative but rather a sleep-promoting substance. It regulates sleep and wake functions, particularly in those experiencing sleep disturbances. This originates from its mechanism in modulating neurotransmitter levels, specifically dopamine, melatonin, 5-HT, and glutamate. Additionally, findings from some studies demonstrate that it crosses the blood-brain barrier more effectively versus other traditional peptides. In restoring neurotransmitter balance, DSIP could lead to improved sleep quality and be used as a treatment for sleep disorders (2).
DSIP has been studied both in the preclinical setting and in humans. In humans, a double-blind study was conducted in 16 chronic insomniac patients. Half the patients were treated with DSIP intravenously while the other half received placebo. Results from the study indicated that individuals treated with DSIP had better sleep quality as demonstrated by higher sleep efficiency and shorter sleep latency versus those on placebo (3). These findings have been replicated in other studies in humans under double-blind conditions as well (4).
In animal studies, rats were treated with intravenous injections of DSIP, and subsequent neurotransmitter levels were measured, including dopamine, norepinephrine, and 5-HT. Marked changes in serotonin levels during the day were observed, and other time-dependent changes in neurotransmitter levels occurred as well outside of just the sleep induction period (5).
Because of research supporting DSIP in neurotransmitter dysregulation and sleep disturbances, it could be a promising treatment option for those seeking sleep-related therapy. However, these investigations had small sample sizes and took place several years ago. More research is needed in well-controlled phase II and III trials in present day.
DSIP is not approved by the FDA for any kind of indication. Additionally, it is not included on the recognized bulk substance list. As such, it isn’t eligible for routine compounding under the 503A/503B regulatory frameworks. DSIP is slated to be discussed at the July 2026 advisory committee meeting regarding its potential inclusion on the 503A bulks list (6).
The FDA warns that compounded drugs including DSIP can carry an immunogenicity risk for specific routes of administration. Additionally, it is not well-characterized and thus there may be some risks associated with peptide-related impurities. Because the FDA does not have sufficient safety-related information on DSIP, they are not aware of its safety profile and risks of the substance (7).
Preliminary evidence shows that DSIP could be useful for those experiencing sleep disturbances. In particular, the available clinical studies show that DSIP could be especially helpful in chronic insomnia. However, although human studies exist, the body of evidence remains small and the safety profile is yet to be fully characterized.
The information provided in this article is for educational purposes only and is not intended as medical advice. Many peptides are not FDA-approved for human use outside of limited clinical contexts. These compounds are often obtained through unregulated sources that lack quality control. Studies suggest 30–65% of products may be contaminated or mislabeled, with risks including endotoxins, heavy metals, and incorrect sequences. At Weight Loss & Vitality, we focus on evidence-based, medically supervised therapies.
As of April 21, 2026, regulatory status for many peptides remains under review and may change as additional data and guidance become available.
References
